SCHEMBL2431466

SCHEMBL2431466

CCN(CC)CCOCc1ccccc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.56
CYP2D6 P10635 2/20 0.56
LTA4H P09960 1/20 0.56
CYP2C9 P11712 1/20 0.56
CYP2C19 P33261 1/20 0.56
HTT P42858 1/20 0.56
DRD3 P35462 3/20 0.53
DRD1 P21728 2/20 0.53
DRD2 P14416 1/20 0.53
TSHR P16473 1/20 0.52
CHRM2 P08172 3/20 0.48
CHRM1 P11229 3/20 0.48
KCNH2 Q12809 2/20 0.48
HTR1A P08908 1/20 0.48
ADRA2A P08913 1/20 0.48
SLC6A2 P23975 1/20 0.48
SLC6A4 P31645 1/20 0.48
ADRA1A P35348 1/20 0.48
OPRM1 P35372 1/20 0.48
SLC6A3 Q01959 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31036634 0.90 DRD3 (0.47) CYP1A2CYP2D6LTA4HCYP2C9CYP2C19
SCHEMBL21172037 0.89 KCNH2 (0.55) CYP1A2CYP2D6LTA4HCYP2C9CYP2C19
SCHEMBL12531323 0.88 DRD1 (0.46) CYP1A2CYP2D6LTA4HCYP2C9CYP2C19
SCHEMBL13136746 0.87 TSHR (0.56) DRD3DRD1DRD2TSHROPRM1
SCHEMBL31036611 0.85 TSHR (0.46) CYP1A2CYP2D6LTA4HCYP2C9CYP2C19
SCHEMBL24486783 0.83 CHRM2 (0.56) CYP1A2CYP2D6LTA4HCYP2C9CYP2C19
SCHEMBL4505794 0.83 TSHR (0.50) HTTTSHRCHRM2CHRM1LMNA
SCHEMBL7057892 0.83 AGXT (0.44) CYP1A2CYP2D6LTA4HCYP2C9CYP2C19
SCHEMBL12198807 0.83 TSHR (0.56) CYP1A2CYP2D6LTA4HCYP2C9CYP2C19
SCHEMBL11465304 0.82 TSHR (0.54) LTA4HTSHROPRM1BCHEALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8012956-B2 Tropane compounds EXELIXIS, INC. (US) 2011-09-06 US claimed
EP-2074120-B1 TROPANE COMPOUNDS EXELIXIS INC (US) 2010-03-03 EP claimed
EP-2074120-A1 TROPANE COMPOUNDS Exelixis, Inc. (US) 2009-07-01 EP claimed
US-20090163471-A1 Tropane compounds EXELIXIS, INC. 2009-06-25 US claimed
WO-2009055077-A1 TROPANE COMPOUNDS EXELIXIS, INC. (US) 2009-04-30 WO claimed
US-8012956-B2 Tropane compounds EXELIXIS, INC. (US) 2011-09-06 US disclosed
EP-2074120-B1 TROPANE COMPOUNDS EXELIXIS INC (US) 2010-03-03 EP disclosed
EP-2074120-A1 TROPANE COMPOUNDS Exelixis, Inc. (US) 2009-07-01 EP disclosed
US-20090163471-A1 Tropane compounds EXELIXIS, INC. 2009-06-25 US disclosed
WO-2009055077-A1 TROPANE COMPOUNDS EXELIXIS, INC. (US) 2009-04-30 WO disclosed
EP-0774966-A4 BENZOFURAN COMPOUNDS, COMPOSITIONS, AND METHODS LILLY CO ELI (US) 1998-01-07 EP disclosed
EP-0774966-A1 BENZOFURAN COMPOUNDS, COMPOSITIONS, AND METHODS ELI LILLY AND COMPANY (US) 1997-05-28 EP disclosed
WO-1996009040-A1 BENZOFURAN COMPOUNDS, COMPOSITIONS, AND METHODS ELI LILLY AND COMPANY (US) 1996-03-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090163471-A1 Tropane compounds ADRA1B, ADRA2B, ADRB2 CYP1A2 17/4885CYP2D6 53/4885LTA4H 649/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.